https://mindmedicinelaw.com/briefing/dea-lists-hexahydrocannabinol-as-schedule-i-substance-20260504-362Psychedelic Research Journalen2026-05-05T22:44:51.430946+00:00DEA Lists Hexahydrocannabinol as Schedule I SubstanceDEA, hexahydrocannabinol, Schedule I, Controlled Substances Act, cannabinoids, psychedelic research, drug policy, HHC regulation, legal compliance, public healthhttps://mindmedicinelaw.com/briefing/fda-s-rolling-review-of-comp360-psilocybin-therapy-20260504-484Psychedelic Research Journalen2026-05-05T22:44:40.800354+00:00FDA's Rolling Review of COMP360 Psilocybin TherapyFDA rolling review, COMP360 psilocybin therapy, COMPASS Pathways, depression treatment, psychedelic research, drug approval process, mental health, regulatory strategy, clinical trials, market impacthttps://mindmedicinelaw.com/briefing/dea-schedules-synthetic-cannabinoids-as-schedule-i-substances-20260501-368Psychedelic Research Journalen2026-05-05T22:44:29.527091+00:00DEA Schedules Synthetic Cannabinoids as Schedule I SubstancesDEA, synthetic cannabinoids, Schedule I, controlled substances, research regulation, public health, policy implications, regulatory burdens, drug enforcement, substance abusehttps://mindmedicinelaw.com/briefing/mdma-therapy-for-ptsd-us-military-s-2027-initiative-20260430-488Psychedelic Research Journalen2026-05-05T22:43:59.179061+00:00MDMA Therapy for PTSD: US Military's 2027 InitiativeMDMA therapy, PTSD treatment, US military, psychedelic research, mental health, clinical trials, policy implications, regulatory approval, psychedelic therapies, military mental healthhttps://mindmedicinelaw.com/briefing/psychedelics-executive-order-shifts-u-s-policy-focus-20260428-485Psychedelic Research Journalen2026-05-05T22:44:17.909817+00:00Psychedelics: Executive Order Shifts U.S. Policy Focuspsychedelics, executive order, Schedule I, treatment priority, clinical trials, mental health, drug policy reform, therapeutic use, research funding, regulatory frameworkhttps://mindmedicinelaw.com/briefing/fda-reschedules-marijuana-to-schedule-iii-policy-shift-20260428-335Psychedelic Research Journalen2026-05-05T22:44:08.374727+00:00FDA Reschedules Marijuana to Schedule III: Policy ShiftFDA rescheduling, Schedule III marijuana, Controlled Substances Act, medical marijuana policy, marijuana research, federal drug policy, state medical marijuana, marijuana regulation, THC products, international drug treaties